Dr James Garner is CEO of Kazia Therapeutics Limited, an ASX- and NASDAQ-listed, oncology-focused biotech company, based in Sydney Australia. Kazia’s lead program, GDC-0084, was licensed from Genentech in October 2016, and is due to enter a phase II clinical trial in glioblastoma multiforme. A second program, Cantrixil, is currently in a phase I trial for ovarian cancer.
Prior to joining Kazia, Dr Garner held senior leadership positions with Sanofi and Takeda, where he was responsible for R&D in the Asia-Pacific region. He has also worked with Biogen, Quintiles, and with several small, innovative biotech companies. Before coming into industry, he worked as a management consultant with Bain & Company.
Dr Garner is a physician by training, and also holds an MBA from the University of Queensland, Australia.